One medical technology firm is well-positioned to navigate its two biggest risk factors and re-rate higher, Goldman Sachs analysts argue ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE